PROTECT YOUR DNA WITH QUANTUM TECHNOLOGY
Orgo-Life the new way to the future Advertising by AdpathwayA clinical team in China has documented more than forty months of sustained deep molecular remission in a forty-year-old patient diagnosed with high-risk B-cell acute lymphoblastic leukemia alongside well-controlled human immunodeficiency virus infection and three severe prognostic risk factors. The clinical case, published in Frontiers in Oncology by researchers at Guangzhou Eighth People’s Hospital at Guangzhou Medical University, describes how an integrated, risk-adapted management strategy achieved durable disease control without human immunodeficiency virus virologic breakthrough. Historically, individuals living with human immunodeficiency virus have faced systematically worse clinical trajectories when developing acute lymphoblastic leukemia, characterized by heightened disease aggressiveness, diminished immune surveillance, greater therapeutic toxicity, and inferior survival compared with uninfected individuals. Moreover, such individuals have been routinely excluded from major clinical trials evaluating bispecific T-cell engager immunotherapy, leaving clinicians with little real-world evidence regarding the safety, feasibility, and therapeutic efficacy of modern immunotherapeutic approaches in this vulnerable population.
The patient presented on March 24, 2023, exhibiting gingival bleeding lasting three weeks alongside a three-day history of fever, superimposed upon a five-year diagnosis of human immunodeficiency virus infection and a two-year history of type 2 diabetes mellitus managed with oral metformin. His initial antiretroviral therapy consisted of tenofovir disoproxil fumarate, efavirenz, and lamivudine, under which his viral load was well controlled at fewer than twenty copies of viral ribonucleic acid per milliliter. Physical examination identified marked pallor and splenomegaly extending approximately three centimeters below the left costal margin without superficial lymphadenopathy or sternal tenderness. Initial laboratory evaluations disclosed extreme hyperleukocytosis with a white blood cell count of 309 times ten to the ninth power per liter, severe anemia with hemoglobin at sixty-two grams per liter, severe thrombocytopenia with platelets at twenty-six times ten to the ninth power per liter, and circulating blasts constituting ninety-one percent of all leukocytes. Elevated serum lactate dehydrogenase reached 636 units per liter and serum uric acid stood at 584.5 micromoles per liter, against normal creatinine levels.
Following two days of oral cytoreductive hydroxyurea therapy at one gram three times daily, laboratory re-evaluation confirmed persistent profound hematologic perturbation, with white blood cell counts at 253.65 times ten to the ninth power per liter, hemoglobin at fifty-three grams per liter, and platelets at twenty times ten to the ninth power per liter. Automated differential testing quantified neutrophils at 12.35, lymphocytes at 214.64, and monocytes at 26.53 times ten to the ninth power per liter. Immunological baseline profiling recorded a CD4-positive T-cell count of 1090 cells per microliter and a CD8-positive T-cell count of 2272 cells per microliter, yielding an inverted CD4-to-CD8 ratio of 0.48. Bone marrow evaluation performed on the second hospital day demonstrated marked hypercellularity with ninety-six percent blast cells expressing classic B-lineage surface markers CD19, CD79a, and HLA-DR while completely lacking CD10, CD34, CD20, myeloid, or T-cell markers. Cytogenetic karyotyping showed a normal 46,XY male profile, while molecular testing identified the high-risk KMT2A::AFF1 fusion resulting from translocation t(4;11) in 95.2 percent of analyzed cells, concurrent with three distinct TP53 mutations spanning exons 5 and 8.
Because presenting white blood cell counts exceeding thirty times ten to the ninth power per liter, KMT2A rearrangements, and TP53 mutations each independently confer profound resistance to standard cytotoxic chemotherapy and rapid relapse, the clinical team deployed an aggressive pretreatment cytoreductive protocol. Initial intervention paired therapeutic leukapheresis with eleven milligrams of once-daily intravenous dexamethasone and a single intravenous dose of 1840 milligrams of cyclophosphamide, reducing the white blood cell count to 75.85 times ten to the ninth power per liter prior to induction. Concurrent tumor lysis syndrome prophylaxis combined forty milligrams of daily oral febuxostat, one gram of oral sodium bicarbonate three times daily, and twenty milligrams of intravenous furosemide daily across five days. Recognizing that efavirenz induces hepatic enzymes and risks major pharmacokinetic interactions with antileukemic agents, a multidisciplinary team of hematologists and infectious disease specialists restructured the antiretroviral regimen. Tenofovir disoproxil fumarate and efavirenz were promptly discontinued, lamivudine was retained, and albuvirtide alongside dolutegravir were introduced for approximately one month, successfully preserving viral suppression below twenty copies per milliliter.
Systemic induction chemotherapy proceeded using the multi-agent VDCLP regimen, comprising vincristine, daunorubicin, cyclophosphamide, L-asparaginase, and prednisone. During this intensive induction phase, the patient developed severe grade IV bone marrow suppression complicated by polymicrobial sepsis caused by Staphylococcus haemolyticus and Pseudomonas aeruginosa, which the medical team successfully resolved through prompt intravenous administration of meropenem and vancomycin. Comprehensive bone marrow assessment conducted on day twenty-one of induction therapy revealed complete hematologic remission, characterized by the complete absence of detectable leukemic blasts and approximately nine percent mature lymphocytes. Flow cytometric immunophenotyping confirmed measurable residual disease clearance below ten to the negative fourth power, while polymerase chain reaction analyses showed undetectable levels of both the KMT2A::AFF1 fusion transcript and the previously identified TP53 gene mutations. This rapid molecular clearance established an essential window of chemosensitivity, demonstrating that the dominant malignant clone had been effectively eliminated despite harboring aggressive cytogenetic and molecular lesions historically linked to early chemoresistance.
Exploiting the therapeutic window provided by complete molecular remission, the clinical team initiated early consolidation with blinatumomab, a CD19-directed bispecific T-cell engager administered at twenty-eight micrograms daily via continuous intravenous infusion across fourteen days. Despite the theoretical requirement for functional host T-cell engagement and the presence of underlying human immunodeficiency virus infection, the first infusion cycle proved well tolerated without unexpected immune toxicities or viral reactivation. The patient subsequently embarked on an intensive twelve-month consolidation sequence incorporating rotating cytotoxic regimens alongside a second cycle of blinatumomab. Systemic therapy integrated sequential cyclophosphamide, cytarabine, mercaptopurine, and high-dose methotrexate, interspersed with three high-risk consolidation blocks designated HR1 prime, HR2 prime, and HR3 prime. All three intensive blocks combined dexamethasone and pegaspargase, paired respectively with vincristine, methotrexate, cyclophosphamide, and cytarabine in HR1 prime; vincristine, methotrexate, ifosfamide, and idarubicin in HR2 prime; and high-dose cytarabine and etoposide in HR3 prime, complemented by central nervous system prophylaxis using intrathecal methotrexate, cytarabine, and dexamethasone.
Approximately fourteen months after initial diagnosis, following sustained measurable residual disease negativity, the patient underwent autologous hematopoietic stem cell transplantation as a consolidating cellular therapy. Although allogeneic stem cell transplantation remains the standard curative modality for many patients harboring KMT2A-rearranged acute lymphoblastic leukemia, elevated risks of severe graft-versus-host disease, opportunistic infections, and transplant-related mortality often preclude its safe application in individuals living with human immunodeficiency virus. Conditioning therapy prior to stem cell infusion utilized high-dose cytarabine combined with busulfan and cyclophosphamide. The patient achieved successful neutrophil engraftment on day nine post-transplantation, followed by platelet engraftment on day twelve. Post-transplant complications were restricted to localized oral mucositis and transient infections, both of which were managed successfully with targeted supportive care, enabling hospital discharge approximately two weeks after stem cell infusion.
Following hospital discharge, the clinicians established a planned two-year maintenance regimen designed to suppress minimal residual clones and prevent late recurrence while maintaining viral stability. Maintenance chemotherapy alternated standard cytotoxic oral and intravenous agents—specifically oral mercaptopurine, methotrexate, vincristine, and dexamethasone—with blinatumomab infusions administered intermittently every four months. Throughout this extended maintenance phase, continuous infection prophylaxis was maintained using daily oral trimethoprim-sulfamethoxazole at 0.48 grams once daily to mitigate the heightened risk of Pneumocystis jirovecii pneumonia secondary to chronic cellular immunosuppression. The patient successfully completed the planned two-year maintenance schedule without treatment discontinuation, terminating therapy as scheduled in August 2026. Routine serial molecular testing, viral surveillance, and bone marrow biopsies conducted across the maintenance period verified that measurable residual disease remained consistently negative, with human immunodeficiency virus viral loads continually suppressed below twenty copies per milliliter.
Longitudinal monitoring of cellular and humoral immunity revealed profound, phase-dependent remodeling throughout the entire therapeutic trajectory. Induction chemotherapy triggered sharp drops across CD4-positive and CD8-positive T-cell compartments, accompanied by steep reductions in peripheral lymphocytes and circulating immunoglobulin G levels. The most severe synchronized immunosuppression manifested during conditioning and stem cell transplantation, where CD4-positive T cells reached a nadir of approximately sixty cells per microliter, absolute lymphocyte counts declined to 0.46 times ten to the ninth power per liter, and B lymphocytes became completely undetectable. Following transplantation, immune reconstitution proceeded slowly in a CD8-predominant pattern, maintaining an inverted ratio between 0.21 and 0.23 alongside persistently low immunoglobulin G concentrations between three and six grams per liter. Notably, circulating CD19-positive B cells remained profoundly suppressed throughout consolidation, transplantation, and maintenance. In CD19-directed immunotherapies, prolonged B-cell aplasia serves as a recognized pharmacodynamic marker of ongoing immunological surveillance against residual malignant clones, suggesting that combined cytotoxic and bispecific therapy sustained durable immune suppression of CD19-positive lineages.
At the final documented clinical evaluation on August 4, 2026, more than forty months following initial diagnosis, the patient remained in continuous deep molecular remission with measurable residual disease below seven times ten to the negative sixth power. Polymerase chain reaction assays confirmed that both KMT2A::AFF1 fusion transcripts and TP53 mutations remained completely undetectable, while human immunodeficiency virus viral ribonucleic acid remained fully suppressed. Immunological measurements at this visit documented CD4-positive and CD8-positive T-cell counts of seventy and sixty-two cells per microliter, respectively, reflecting an adjusted CD4-to-CD8 ratio of 1.13 alongside persistent B-cell depletion and suppressed immunoglobulin levels. Despite these favorable long-term outcomes, the authors emphasize several critical clinical limitations and scientific uncertainties. Because the patient received a complex multi-agent treatment regimen combining intensive chemotherapy, bispecific antibodies, and autologous transplantation, the specific individual contribution of blinatumomab cannot be isolated. Furthermore, marked T-cell depletion observed during late treatment stages, coupled with the lack of functional T-cell assays, leaves the true biological efficacy of late blinatumomab cycles uncertain. Consequently, these findings from a single carefully selected patient with well-controlled infection cannot be extrapolated to individuals with poorly controlled viral replication, and prospective clinical investigations remain essential to define validated immunological thresholds and standardized treatment strategies for this ultra-high-risk cohort.
Subject of Research: Targeted immunotherapy and autologous stem cell transplantation in HIV-associated high-risk acute lymphoblastic leukemia
Article Title: Case Report: 40-month durable deep molecular remission after blinatumomab + autologous HSCT in a high-risk B-ALL patient with HIV infection and triple risk factors
Article References: Chen, L., Zhang, Y., Zhong, T., Jia, L., Tian, M., Ai, J., Chen, J., & Peng, J. (2026). Case Report: 40-month durable deep molecular remission after blinatumomab + autologous HSCT in a high-risk B-ALL patient with HIV infection and triple risk factors. Frontiers in Oncology, 16, Article 2003508. https://doi.org/10.3389/fonc.2026.2003508
Image Credits: AI Generated
DOI: 10.3389/fonc.2026.2003508
Keywords: B-cell acute lymphoblastic leukemia, blinatumomab, autologous hematopoietic stem cell transplantation, human immunodeficiency virus, KMT2A-AFF1 rearrangement, TP53 mutations, hyperleukocytosis, measurable residual disease, antiretroviral therapy optimization, bispecific T-cell engager, immune reconstitution, B-cell aplasia, albuvirtide, dolutegravir, induction chemotherapy, hematologic malignancies, consolidation therapy


3 hours ago
11




















English (US) ·
French (CA) ·